EP4119160A4 - Medikament zur behandlung und/oder prävention von krebs - Google Patents

Medikament zur behandlung und/oder prävention von krebs Download PDF

Info

Publication number
EP4119160A4
EP4119160A4 EP21768434.9A EP21768434A EP4119160A4 EP 4119160 A4 EP4119160 A4 EP 4119160A4 EP 21768434 A EP21768434 A EP 21768434A EP 4119160 A4 EP4119160 A4 EP 4119160A4
Authority
EP
European Patent Office
Prior art keywords
cancer
medicine
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21768434.9A
Other languages
English (en)
French (fr)
Other versions
EP4119160A1 (de
Inventor
Fumiyoshi Okano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of EP4119160A1 publication Critical patent/EP4119160A1/de
Publication of EP4119160A4 publication Critical patent/EP4119160A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP21768434.9A 2020-03-12 2021-03-11 Medikament zur behandlung und/oder prävention von krebs Pending EP4119160A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020043022 2020-03-12
PCT/JP2021/009799 WO2021182574A1 (ja) 2020-03-12 2021-03-11 癌の治療及び／又は予防のための医薬品

Publications (2)

Publication Number Publication Date
EP4119160A1 EP4119160A1 (de) 2023-01-18
EP4119160A4 true EP4119160A4 (de) 2024-04-03

Family

ID=77670660

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21768434.9A Pending EP4119160A4 (de) 2020-03-12 2021-03-11 Medikament zur behandlung und/oder prävention von krebs

Country Status (7)

Country Link
US (1) US20230159635A1 (de)
EP (1) EP4119160A4 (de)
JP (2) JPWO2021182574A1 (de)
KR (1) KR20220151684A (de)
BR (1) BR112022018161A2 (de)
CA (1) CA3175279A1 (de)
WO (1) WO2021182574A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911926A2 (pt) * 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
CN118852442A (zh) * 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013125630A1 (ja) * 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2019189780A1 (ja) * 2018-03-30 2019-10-03 東レ株式会社 癌の治療及び／又は予防用医薬組成物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
US8811201B2 (en) * 2008-04-18 2014-08-19 Telefonaktiebolaget Lm Ericsson (Publ) Access network selection in a multi-access network environment
BRPI0911926A2 (pt) * 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
EP2711018A1 (de) 2009-06-22 2014-03-26 MedImmune, LLC Manipulierte Fc-Regionen für standortspezifische Konjugation
EP2480671B8 (de) 2009-09-22 2015-10-28 ProBioGen AG Verfahren zur herstellung von molekülen mit spezialisierten glykanstrukturen
DK2532680T3 (da) * 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
CA2788545C (en) * 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
US9115200B2 (en) 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
EP2740794B1 (de) 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmazeutische zusammensetzung zur behandlung und/oder prävention von krebs
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
PL2740793T3 (pl) 2011-08-04 2018-04-30 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
WO2013125654A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び／又は予防用医薬組成物
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US9177410B2 (en) * 2013-08-09 2015-11-03 Ayla Mandel System and method for creating avatars or animated sequences using human body features extracted from a still image
AU2016271138A1 (en) * 2015-05-29 2017-12-07 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
JP2020043022A (ja) 2018-09-13 2020-03-19 オンキヨー株式会社 面状発光装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013125630A1 (ja) * 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2019189780A1 (ja) * 2018-03-30 2019-10-03 東レ株式会社 癌の治療及び／又は予防用医薬組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors - Full Text View - ClinicalTrials.gov", 13 March 2019 (2019-03-13), pages 1 - 10, XP093131779, Retrieved from the Internet <URL:https://classic.clinicaltrials.gov/ct2/show/NCT03872947> [retrieved on 20240215] *
LARKIN JAMES ET AL: "Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 381, no. 16, 17 October 2019 (2019-10-17), US, pages 1535 - 1546, XP093133323, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1910836 *
See also references of WO2021182574A1 *

Also Published As

Publication number Publication date
CA3175279A1 (en) 2021-09-16
JPWO2021182574A1 (de) 2021-09-16
WO2021182574A1 (ja) 2021-09-16
JP2025181951A (ja) 2025-12-11
EP4119160A1 (de) 2023-01-18
BR112022018161A2 (pt) 2022-10-25
KR20220151684A (ko) 2022-11-15
US20230159635A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
EP3777888A4 (de) Pharmazeutische zusammensetzung zur behandlung und/oder prävention von krebs
EP4115887A4 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von krebs mit kras-mutation und aktiviertem ron
EP4171548A4 (de) Kombinationstherapie zur behandlung von krebs
EP3672594A4 (de) Kombinationsprodukt aus bcl-2-inhibitor und mdm2-inhibitor und verwendung davon zur prävention und/oder behandlung von krankheiten
EP4139454A4 (de) Zusammensetzungen zur behandlung von krebsmutationen und verwendungen davon
EP4125846A4 (de) Pyrazolylpropanamidverbindungen und verwendungen davon zur behandlung von prostatakrebs
EP4221838A4 (de) Snca-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von snca-assoziierten neurodegenerativen erkrankungen
EP4094754C0 (de) Zusammensetzungen zur behandlung und/oder prävention von proteinaggregationserkrankungen
EP3566710A4 (de) Therapeutikum und anwendung davon in arzneimitteln zur behandlung von tumoren und/oder krebs
EP4438048A4 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von t-zell-bedingten erkrankungen
EP4403182A4 (de) Medikament zur behandlung und/oder prävention von krebs
EP4119158A4 (de) Medikament zur behandlung und/oder prävention von krebs
EP4119160A4 (de) Medikament zur behandlung und/oder prävention von krebs
EP4125893A4 (de) Technologien zur prävention oder behandlung von infektionen
EP4364740A4 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von krebs
EP4378478A4 (de) Medikament zur behandlung und/oder prävention von krebs
EP4422608A4 (de) Endoxifen zur behandlung von krebs
EP4176880A4 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von krebs mit 3-ketoacyl-coa-thiolasehemmer und carnitinacylcarnitinträgerhemmer
EP3999112A4 (de) Tumorvakzinzusammensetzungen und verfahren zur verwendung davon zur prävention und/oder behandlung von krebs
EP4017496C0 (de) Formulierungen zur vorbeugung und/oder behandlung von peripherer neuropathie und deren assoziierten erkrankungen
EP4512401A4 (de) Arzneimittel zur behandlung oder prävention von krebs
EP4378477A4 (de) Medikament zur behandlung und/oder prävention von krebs
EP4378476A4 (de) Medikament zur behandlung und/oder prävention von krebs
EP4360648A4 (de) Medikament zur behandlung und/oder prävention von krebs
EP4401738A4 (de) Arzneimittel zur prävention und/oder behandlung des trockenen auges

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221003

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240301

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/30 20060101ALI20240226BHEP

Ipc: A61P 43/00 20060101ALI20240226BHEP

Ipc: A61P 37/02 20060101ALI20240226BHEP

Ipc: A61P 35/00 20060101ALI20240226BHEP

Ipc: A61K 45/00 20060101ALI20240226BHEP

Ipc: A61K 39/395 20060101AFI20240226BHEP